Airnov Showcases its New Branding Strategy at Pharmapack 2020

Article

Airnov announced on Feb. 5, 2020 at Pharmapack in Paris, France, that it will move forward as an independent company focused on desiccant and oxygen scavenging products for the pharmaceutical, diagnostic, and nutraceutical markets.

Airnov, a healthcare packaging company formerly owned by Clariant, announced on Feb. 5, 2020 at Pharmapack in Paris, France, that it will move forward as an independent company focused on desiccant and oxygen scavenging products for the pharmaceutical, diagnostic, and nutraceutical markets.

As part of its new branding strategy, the company is currently developing environmentally friendly packaging solutions using advanced desiccant polymer (ADP) technology, a desiccant that is integrated directly in the polymer matrix for moisture management, a company press release said. At Pharmapack, the company focused on two commercial launches that used ADP technology, the ADP plate for nutraceutical powder and medical device protection, and the HAT-IN vial with an ADP layer for test strips protection.

"Airnov's newly gained independence and subsequent shorter in-company decision-making lines will make us more flexible and better able to meet customer needs in terms of technical support, product innovation and new developments,” said Dr. Matthias Brommer, president and managing director, Airnov. “Our focus will be on delivering exceptional service, innovation and sustainability, as we rededicate some of the time and attention previously required for corporate processes to help us better focus on fulfilling customer requirements and expectations."

“Our goal is to significantly expand above and beyond current pharmaceutical packaging market growth rates, with new investments, products and technologies, both organically and by acquisition. We continue to look for and evaluate relevant opportunities,” Brommer added in the press release.

Source: Airnov

 

 

 

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content